Agios Pharm (NASDAQ: AGIO) — Perfil da empresa, notícias e dados financeiros
Agios Pharm is dedicated to developing therapeutics for cancer and rare genetic disorders, emphasizing precision medicine approaches.
Agios Pharm
Agios Pharm (NASDAQ:AGIO) focuses on the discovery and development of therapeutics in the fields of cancer and rare genetic disorders. With a commitment to leveraging scientific advances to offer new treatment options, Agios has initiated various projects aimed at targeting cellular metabolism and precision medicine. Its objectives include advancing its pipeline of novel drug candidates through clinical trials, with the goal of improving patient outcomes in areas with unmet medical needs. Emphasizing collaboration with healthcare professionals and regulatory bodies, Agios aims to bring transformative therapies from the lab to the bedside, ensuring access to innovative treatments for patients worldwide.
Resumo
Operações
Produtos e/ou serviços de Agios Pharm
- Mitapivat, first-in-class therapy for adults with pyruvate kinase (PK) deficiency to improve hemoglobin levels and reduce transfusion need.
- Research in oncology focusing on genetically defined diseases with a pipeline targeting metabolic pathways for cancer treatment.
- Collaborations with biotech and pharmaceutical companies to accelerate the development and commercialization of novel therapeutics in areas of high unmet medical need.
- Advancements in rare hematologic diseases, exploring novel therapeutic approaches for conditions with limited treatment options.
- Development of a next-generation PK activator designed to offer a more potent and selective treatment option for PK deficiency.
- Continuation and expansion of patient assistance programs aiming to ensure access to treatments for underprivileged patients.
equipe executiva do Agios Pharm
- Brian M. GoffCEO & Director
- Cecilia JonesChief Financial Officer
- Krishnan ViswanadhanChief Strategy & Operations Officer
- James William BurnsChief Legal Officer
- Sarah GheuensChief Medical Officer and Head of Research & Development
- Lewis clayton CantleyCo-Founder
- Tak Wah MakCo-Founder
- Craig B. ThompsonCo-Founder
- Shin-San SuCo-Founder
- T. J. WashburnVP, Controller & Principal Accounting Officer
Últimas notícias sobre a Agios Pharm
Agios licenses oral blood disorder drug from Oscotec in $165M deal
United StatesAgios discontinues tebapivat program in lower-risk myelodysplastic syndromes after Phase 2b trial fails
United StatesEU approves Agios’ Pyrukynd as first oral treatment for adult thalassemia
United StatesAgios reports Q4 2025 PYRUKYND net revenue of $20M
United StatesFDA approves Agios’ AQVESME™ for all thalassemia subtypes
United States
Principais indicadores financeiros
Resultados divulgados pela Agios Pharm, em USD.
- Cap. de mercado
- 2,3 bi
- Receita (TTM)
- 98,3 mi
- P/L
- —
- LPA (diluído, TTM)
- -7.0
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 54 mi | -472,1 mi | -412,8 mi | |
| 36,5 mi | -425,7 mi | 673,7 mi | |
| 26,8 mi | -391,5 mi | -352,1 mi | |
| 14,2 mi | -389 mi | -231,8 mi |